收藏切换
Population pharmacokinetics and pharmacodynamics of a novel GLP-1 analogue in type 2 diabetes patient
收藏切换
PDF
Na XIE1, Min-guang ZHANG2, Run NAN2, Si-qi WANG1, Ya-he ZHU1, Ying WU1, Heng-hui LIU2
Chinese Journal of Clinical Pharmacology | 2026, 42(6) : 820 - 827
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(6): 820-827
Pharmacokinetics and Bioequivalence Study
Population pharmacokinetics and pharmacodynamics of a novel GLP-1 analogue in type 2 diabetes patient
Full
Na XIE1, Min-guang ZHANG2, Run NAN2, Si-qi WANG1, Ya-he ZHU1, Ying WU1, Heng-hui LIU2
Affiliations
  • 1.School of Public Health, North China University of Science and Technology, Tangshan 063210, Hebei Province, China
  • 2.Beijing Yurong Medical Data Technology Co., Ltd., Beijing 100176, China
Published: 2026-03-28 doi: 10.13699/j.cnki.1001-6821.2026.06.011
Outline
收藏切换
Objective

To establish a population pharmacokinetic-pharmacodynamic (PK-PD) model of a novel glucagon-like peptide-1 (GLP-1) analogue in patients with type 2 diabetes mellitus (T2DM), using HbA1c levels after 52 weeks of treatment as the efficacy endpoint and based on a nonlinear mixed-effects model (NLME).

Methods

A population PK-PD linkage model was developed via the NLME approach, utilizing 1 967 plasma concentration data points and 1 813 observed HbA1c data points from 409 T2DM subjects enrolled in a Phase Ⅲ clinical trial. Model robustness and predictive performance were comprehensively validated using diagnostic plots, visual predictive check (VPC), and the Bootstrap method.

Results

The PK characteristics were best described by a one-compartment model with first-order absorption and first-order elimination, while the PD model was a plasma concentration-driven indirect response model. Key parameters were estimated as follows: apparent volume of distribution (V/F)=11.28 L, apparent clearance (CL/F)=1.11 L·day-1, maximum inhibitory effect (Imax)=0.30, and half-maximal inhibitory concentration (IC50)=37.77 ng·mL-1. Covariate analysis revealed that baseline body weight was a significant factor affecting CL/F, and baseline HbA1c (group 1: HbA1c < 8.5%; group 2: HbA1c ≥ 8.5%) influenced the parameter kin.

Conclusion

The nonlinear mixed-effects model effectively utilizes sparsely sampled data, and the obtained PK-PD parameter estimates are robust and reliable.

GLP-1 analogue  /  nonlinear mixed-effects modeling  /  population pharmacokinetics  /  population pharmacodynamics  /  sparse sampling
Na XIE, Min-guang ZHANG, Run NAN, Si-qi WANG, Ya-he ZHU, Ying WU, Heng-hui LIU. Population pharmacokinetics and pharmacodynamics of a novel GLP-1 analogue in type 2 diabetes patient[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (6) : 820 -827 . DOI: 10.13699/j.cnki.1001-6821.2026.06.011
Year 2026 volume 42 Issue 6
PDF
161
33
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.06.011
  • Receive Date:2026-01-29
  • Online Date:2026-08-06
  • Published:2026-03-28
Article Data
Affiliations
History
  • Received:2026-01-29
Affiliations
    1.School of Public Health, North China University of Science and Technology, Tangshan 063210, Hebei Province, China
    2.Beijing Yurong Medical Data Technology Co., Ltd., Beijing 100176, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.06.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT